Kinase inhibitor

DRUG2 trials

Sponsors

Groupe Hospitalier Pitie-Salpetriere, Immunocore Ltd

Conditions

CancerHLA-A*02:01-positiveKinase Inhibitors Toxicity

Phase 1

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

RecruitingNCT06840119

Immunocore LtdCancer, HLA-A*02:01-positive

Start: 2024-01-10End: 2027-11-30Target: 600Updated: 2026-01-28

Unknown Phase

Identification of PAthways of Kinase Inhibitors TOxicity

CompletedNCT03896139

Groupe Hospitalier Pitie-SalpetriereKinase Inhibitors Toxicity

Start: 2017-01-01End: 2019-03-01Updated: 2019-03-29